Literature DB >> 19293136

Nephropathy in Fabry disease: the importance of early diagnosis and testing in high-risk populations.

Björn Oqvist, Barry M Brenner, João Paulo Oliveira, Alberto Ortiz, Roland Schaefer, Einar Svarstad, Christoph Wanner, Kate Zhang, David G Warnock.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19293136     DOI： 10.1093/ndt/gfp105

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN： 0931-0509            Impact factor:   5.992


× No keyword cloud information.
  12 in total

Review 1.  [Females with Fabry's disease - an interdisciplinary diagnostic and therapeutic challenge].

Authors:  Frank Weidemann; Markus Niemann; Claudia Sommer; Meinrad Beer; Frank Breunig; Christoph Wanner
Journal:  Med Klin (Munich)       Date:  2010-09-28

Review 2.  Lysosomal storage disease overview.

Authors:  Angela Sun
Journal:  Ann Transl Med       Date:  2018-12

3.  Effects of switching from agalsidase Beta to agalsidase alfa in 10 patients with anderson-fabry disease.

Authors:  A Pisani; L Spinelli; B Visciano; I Capuano; M Sabbatini; E Riccio; G Messalli; M Imbriaco
Journal:  JIMD Rep       Date:  2012-10-21

4.  Prognostic indicators of renal disease progression in adults with Fabry disease: natural history data from the Fabry Registry.

Authors:  Christoph Wanner; João P Oliveira; Alberto Ortiz; Michael Mauer; Dominique P Germain; Gabor E Linthorst; Andreas L Serra; László Maródi; Renzo Mignani; Bruno Cianciaruso; Bojan Vujkovac; Roberta Lemay; Dana Beitner-Johnson; Stephen Waldek; David G Warnock
Journal:  Clin J Am Soc Nephrol       Date:  2010-09-02       Impact factor: 8.237

Review 5.  Anderson-Fabry cardiomyopathy: prevalence, pathophysiology, diagnosis and treatment.

Authors:  Brendan N Putko; Kevin Wen; Richard B Thompson; John Mullen; Miriam Shanks; Haran Yogasundaram; Consolato Sergi; Gavin Y Oudit
Journal:  Heart Fail Rev       Date:  2015-03       Impact factor: 4.214

6.  Characterization and phosphoproteomic analysis of a human immortalized podocyte model of Fabry disease generated using CRISPR/Cas9 technology.

Authors:  Ester M Pereira; Anatália Labilloy; Megan L Eshbach; Ankita Roy; Arohan R Subramanya; Semiramis Monte; Guillaume Labilloy; Ora A Weisz
Journal:  Am J Physiol Renal Physiol       Date:  2016-09-28

7.  A renal variant of Fabry disease: A case with a novel Gal A hemizygote mutation.

Authors:  Jorge H Mukdsi; Silvina Gutiérrez; Belén Barrón; Pablo Novoa; Segundo Fernández; Ana B de Diller; Alicia I Torres; Richard N Formica; Marcelo Orías
Journal:  J Nephropathol       Date:  2012-10-01

8.  Receptor-mediated endocytosis of α-galactosidase A in human podocytes in Fabry disease.

Authors:  Thaneas Prabakaran; Rikke Nielsen; Jakob V Larsen; Søren S Sørensen; Ulla Feldt-Rasmussen; Moin A Saleem; Claus M Petersen; Pierre J Verroust; Erik I Christensen
Journal:  PLoS One       Date:  2011-09-19       Impact factor: 3.240

9.  Renal outcomes of agalsidase beta treatment for Fabry disease: role of proteinuria and timing of treatment initiation.

Authors:  David G Warnock; Alberto Ortiz; Michael Mauer; Gabor E Linthorst; João P Oliveira; Andreas L Serra; László Maródi; Renzo Mignani; Bojan Vujkovac; Dana Beitner-Johnson; Roberta Lemay; J Alexander Cole; Einar Svarstad; Stephen Waldek; Dominique P Germain; Christoph Wanner
Journal:  Nephrol Dial Transplant       Date:  2011-07-29       Impact factor: 5.992

Review 10.  Fibrosis: a key feature of Fabry disease with potential therapeutic implications.

Authors:  Frank Weidemann; Maria D Sanchez-Niño; Juan Politei; João-Paulo Oliveira; Christoph Wanner; David G Warnock; Alberto Ortiz
Journal:  Orphanet J Rare Dis       Date:  2013-08-06       Impact factor: 4.123
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.